Type 1 Diabetes Pipeline Landscape Analysis of 80+ Companies by DelveInsight
Type 1 Diabetes pipeline involves 80+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, as per DelveInsight
/EIN News/ -- New York, USA, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Type 1 Diabetes Pipeline Landscape Analysis of 80+ Companies by DelveInsight
Type 1 Diabetes pipeline involves 80+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, as per DelveInsight
DelveInsight’s 'Type 1 Diabetes Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline type 1 diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the type 1 diabetes pipeline domain.
Key Takeaways from the Type 1 Diabetes Pipeline Report
- DelveInsight’s type 1 diabetes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for type 1 diabetes treatment.
- Key type 1 diabetes companies such as Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others are evaluating new type 1 diabetes drugs to improve the treatment landscape.
- Promising type 1 diabetes pipeline therapies in various stages of development include LABP 111, TTP 399, Teplizumab, Emricasan, VX 880, Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301, Dasiglucagon, SQZ TAC research program, Ent001, and others.
- In July 2022, Vertex Pharmaceuticals announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.
- In June 2022, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold placed on the Phase I/II clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemia awareness and severe hypoglycemia.
- In April 2022, AVM Biotechnology received Small Business Innovation Research (SBIR) award of $1.6m from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) to study its small molecule, AVM0703, for reversing Type 1 diabetes (T1D). The latest grant will permit the company to carry out further research into using AVM0703 as a single agent and as a combination treatment for reversing recent onset and established T1D.
- In May 2022, Sernova and Evotec are pleased to announce an exclusive global strategic partnership to develop a best-in-class cell therapy treatment for people living with insulin-dependent diabetes. The partnership provides Sernova a global exclusive option to license Evotec’s iPSC-based beta cells for use in treating both type 1 and type 2 diabetes. In addition to entering into the collaboration agreement, Evotec has made a strategic equity investment of €15M and will make a further investment of €5M.
- In March 2022, Jaguar Gene Therapy announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes (T1D), have invested in the company.
- In January 2022, Remedium Bio announced it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on Type 1 and Type 2 Diabetes pipeline candidates. The collaboration to evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies.
Request a sample and discover the recent advances in type 1 diabetes treatment drugs @ Type 1 Diabetes Pipeline Outlook
The type 1 diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage type 1 diabetes products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the type 1 diabetes pipeline landscape.
Type 1 Diabetes Overview
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that causes the loss of insulin-producing pancreatic beta cells. Insulin is a necessary anabolic hormone that influences glucose, lipid, protein, and mineral metabolism, as well as growth. The exact type 1 diabetes causes are unknown. T1DM develops in three phases. Stage 1 is asymptomatic and is distinguished by normal fasting glucose, normal glucose tolerance, and the presence of more than or equivalent to two pancreatic autoantibodies. The presence of more than or equal to two pancreatic autoantibodies and dysglycemia: impaired fasting glucose (glucose of 100 to 125 mg/dL) or impaired glucose tolerance (2-hour PG of 140 to 199 mg/dL) or a hemoglobin A1c of 5.7% to 6.4% are stage 2 diagnostic criteria. Individuals stay asymptomatic. Diabetes or hyperglycemia with clinical signs and two or more pancreatic autoantibodies characterize stage 3.
Type 1 diabetes symptoms might occur unexpectedly and include frequent urine, weight loss, blurry vision, tiredness, weakness, and others. The blood test is the most common method for type 1 diabetes diagnosis.
Find out more about type 1 diabetes treatment drugs @ Type 1 Diabetes Medications
A snapshot of the Type 1 Diabetes Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Teplizumab | Prevention Bio | Pre-registration | CD3 antigen inhibitors | Intravenous |
| Dasiglucagon | Zealand Pharma | Phase III | Glucagon receptor agonists | Subcutaneous |
| AT-1501 | Eledon Pharmaceuticals | Phase II | CD40 ligand inhibitors | Intravenous |
| AVT001 | Avotres | Phase II | Cell replacements | Intravenous |
| IMCY-0098 | ImCyse | Phase II | Cytotoxic T lymphocyte stimulants | Subcutaneous |
| Iscalimab | Novartis | Phase II | CD40 ligand inhibitors | Subcutaneous/ Intravenous |
| Emricasan | Histogen | Phase I/II | Apoptosis inhibitors; Caspase inhibitors | Subcutaneous |
| VX-880 | Vertex Pharmaceuticals | Phase I/II | Pancreatic beta cell replacements | Intrahepatic |
| NNC0363 0845 | Novo Nordisk | Phase I | NA | Subcutaneous |
| Eflornithine | Panbela Therapeutics | Phase I | Ornithine decarboxylase inhibitors | Oral |
| LABP 111 | Landos Biopharma | IND | LANCL2 protein stimulants | NA |
Learn more about the novel and emerging type 1 diabetes pipeline therapies @ Type 1 Diabetes Clinical Trials
Type 1 Diabetes Therapeutics Assessment
The type 1 diabetes pipeline report proffers an integral view of the type 1 diabetes emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Type 1 Diabetes Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intravenous, Oral, Subcutaneous
- Therapeutics Assessment By Molecule Type: Cell therapy, Peptide, Small molecule, Polymer, Gene therapy
- Therapeutics Assessment By Mechanism of Action: CD3 antigen inhibitors, Apoptosis inhibitors, Caspase inhibitors, Pancreatic beta cell replacements, Glucagon receptor agonists, LANCL2 protein stimulants, Ornithine decarboxylase stimulants, Immunostimulants and Cytotoxic T lymphocyte stimulants,
- Key Type 1 Diabetes Pipeline Therapies: LABP 111, TTP 399, Teplizumab, Emricasan, VX 880, Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine , ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin , Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301, Dasiglucagon, SQZ TAC research program, Ent001 and others
Dive deep into rich insights for new drugs for type 1 diabetes treatment, visit @ FDA-approved Type 1 Diabetes Drugs
Table of Contents
| 1. | Type 1 Diabetes Pipeline Report Introduction |
| 2. | Type 1 Diabetes Pipeline Report Executive Summary |
| 3. | Type 1 Diabetes Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Type 1 Diabetes Pipeline Therapeutics |
| 6. | Type 1 Diabetes Pipeline: Late Stage Products (Pre-registration) |
| 7. | Teplizumab: Prevention Bio |
| 8. | Type 1 Diabetes Pipeline: Late Stage Products (Phase III) |
| 9. | Dasiglucagon: Zealand Pharma |
| 10. | Type 1 Diabetes Pipeline: Mid Stage Products (Phase II) |
| 11. | IMCY-0098: ImCyse |
| 12 | Type 1 Diabetes Pipeline: Early Stage Products (Phase I) |
| 13. | NNC0363 0845: Novo Nordisk |
| 14. | Type 1 Diabetes Pipeline Therapeutics Assessment |
| 15. | Inactive Products in the Type 1 Diabetes Pipeline |
| 16. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 17. | Key Companies |
| 18. | Key Products in the Type 1 Diabetes Pipeline |
| 19. | Unmet Needs |
| 20. | Market Drivers and Barriers |
| 21. | Future Perspectives and Conclusion |
| 22. | Analyst Views |
| 23. | Appendix |
For further information on the type 1 diabetes pipeline therapeutics, reach out @ Type 1 Diabetes Gene Therapy
Related Reports
Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies including Histogen, Novo Nordisk, Prevention Bio, among others.
Type 1 Diabetes Epidemiology Forecast
Type 1 Diabetes Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted type 1 diabetes epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Diabetes Pipeline Insights, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetes companies, including Prevention Bio, Zealand Pharma, Novo Nordisk, among others.
Diabetes Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.
Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, AstraZeneca, Novartis, among others.
Type 2 Diabetes Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, Novartis, among others.
Other Trending Reports
Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market
Related Healthcare Blogs
Evolution in Diabetes Management
Increasing Prevalence of Diabetes
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
